Prevalence of NAFLD in T1DM Patients

Not Applicable

Recruiting

• Conditions: NAFLD; Type 1 Diabetes; Fatty Liver, Nonalcoholic
• Interventions: Diagnostic Test: FibroScan

• Registration Number: NCT06445361
• Lead Sponsor: Ziekenhuis Oost-Limburg

Brief Summary

To determine the prevalence of NAFLD in T1DM patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-02-01
• Study First Submitted: 2024-02-28
• Status Verified: 2024-05
• Study First Submitted QC: 2024-06-03
• Last Update Submitted: 2024-06-03
• Study First Posted: 2024-06-06
• Last Update Posted: 2024-06-06
• Primary Completion: 2024-11-01
• Study Completion: 2024-11-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 138

Inclusion Criteria

• T1DM
• ≥ 18 years of age
• Written informed consent obtained

Exclusion Criteria

• Excessive alcohol use
• Exclusion of other causes of liver disease and secondary causes of liver steatosis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Study cohort	FibroScan	FibroScan measurement

Primary Outcome Measures

Name	Time	Method
Prevalence of fibrosis in T1DM	During the intervention	To determine the prevalence of fibrosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with vibration controlled attenuation parameter (VCTE) measurements.
Prevalence of NAFLD in T1DM	During the intervention	To determine the prevalence of steatosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with controlled attenuation parameter (CAP) measurements.

Trial Locations

Locations (1)

Ziekenhuis Oost-Limburg; 🇧🇪 Genk, Limburg, Belgium